Abstract
Background: The incidence of malignant pleural mesothelioma (MPM) is anticipated to increase over the next 10 years in both Europe and developing nations. There are many conflicting inferences regarding the prognostic value of clinical variables. The aim of this study is to determinate clinical prognostic factors of patients diagnosed of MPM in our institution. Methods and Patients: Thirty one patients (pts) diagnosed of MPM in our institution between November 2002 and November 2009 were retrospectively reviewed. Baseline prognostic factors analyzed were age, performance status (PS), histology, stage, response rate to chemotherapy (CT) and interval from first diagnosis. Overall survival (OS) and progression free survival (PFS) were calculated by the Kaplan Meier method. Results: Baseline patients characteristics: median age 68 years (52 83 years), males 80.6%, PS 1: 77.4%, asbestos exposure 63.1%, chest pain 74.2%, dyspnea 74.2%, pleural effusion 93.5%, epithelial subtype 67%, stage III: 54.8% and median time from first symptom to diagnosis 2.5 months. All patients were considered initially unresectable and 77.4% of patients received chemotherapy (CT) in first line and 32.3% in second line. After a median follow up of 8.8 months, 27 pts relapsed and 22 had died. The median PFS was 6.7 months and OS was 16.4 months. We found significant increase in OS in patients with epithelial subtype (23.4 months vs 2.3 months in no-epithelial, p 75 years, (p = 0.28), stage III: 22.8m vs 16.4 months in stage IV (p = 0.65), patients with partial response (PR) to CT: 23.3 vs 16.4 months in pts with no response (p = 0.64) and shorter interval from first diagnosis: 22.8m vs 5.6m (p = 0.43). Conclusion: In our analysis, epithelial subtype and treatment with second line therapy are prognostic factor for OS in MPM. Second line CT treatment may have a role in MPM. Disclosure: All authors have declared no conflicts of interest. 97P A NEW 3D CONFORMATIONAL SOLUTION RADIOTHERAPY OF MALIGNANT PLEURAL MESOTHELIOMA
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
